• Tue news: Novo looks to speed up India Wegovy launch. 4 revelations from MN’s 340B transparency report. 4 oral GLP-1R’s in dev. Roche autoimmune partnership. Gilead-Tubulis alliance. See more on our front page

Agendia







Agendia has an amazing product. Mammaprint will soon take over as the gold standard and will leave Oncotype in the dust as a product of the past. That is the good news. The bad news, the VP of Agendia is clueless and is in way over his head. In the long run Agendia will prevail. The CEO is a solid leader and the longterm health of the company is looking good, despite the fact that the current VP is hurting the morale and culture of the salesforce.
 






Agendia has an amazing product. Mammaprint will soon take over as the gold standard and will leave Oncotype in the dust as a product of the past. That is the good news. The bad news, the VP of Agendia is clueless and is in way over his head. In the long run Agendia will prevail. The CEO is a solid leader and the longterm health of the company is looking good, despite the fact that the current VP is hurting the morale and culture of the salesforce.
Hahahaha this was as idiotic then as it is now